Money Concepts Capital Corp Has $2.25 Million Holdings in Merck & Co., Inc. $MRK

Money Concepts Capital Corp increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 30.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 18,737 shares of the company’s stock after acquiring an additional 4,382 shares during the period. Money Concepts Capital Corp’s holdings in Merck & Co., Inc. were worth $2,254,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $31,000. Finally, High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK traded down $1.35 during midday trading on Friday, reaching $123.72. The company’s stock had a trading volume of 8,388,403 shares, compared to its average volume of 10,797,806. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The company has a market capitalization of $305.56 billion, a P/E ratio of 34.85, a P/E/G ratio of 2.68 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business’s fifty day simple moving average is $118.83 and its 200-day simple moving average is $116.28.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were paid a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MRK shares. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. CICC Research started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price for the company. Finally, Wells Fargo & Company boosted their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $132.72.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.